Back to top
more

Compugen (CGEN)

(Delayed Data from NSDQ)

$1.46 USD

1.46
184,093

-0.02 (-1.35%)

Updated Aug 4, 2025 04:00 PM ET

After-Market: $1.46 0.00 (0.00%) 4:42 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Teladoc (TDOC) Moves 14.4% Higher: Will This Strength Last?

by Zacks Equity Research

Teladoc (TDOC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Exelixis (EXEL) Surges 7.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Exelixis (EXEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?

by Zacks Equity Research

Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?

by Zacks Equity Research

XOMA Royalty (XOMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Strength Seen in Brainsway (BWAY): Can Its 5.3% Jump Turn into More Strength?

by Zacks Equity Research

Brainsway (BWAY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

RGC Resources (RGCO) Surges 9.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

RGC Resources (RGCO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Graham (GHM) Surges 7.4%: Is This an Indication of Further Gains?

by Zacks Equity Research

Graham (GHM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

GeneDx Holdings (WGS) Moves 19.0% Higher: Will This Strength Last?

by Zacks Equity Research

GeneDx Holdings (WGS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Strength Seen in Mobileye (MBLY): Can Its 11.6% Jump Turn into More Strength?

by Zacks Equity Research

Mobileye (MBLY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Equity Research

EchoStar (SATS) Moves 49.1% Higher: Will This Strength Last?

by Zacks Equity Research

EchoStar (SATS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Zacks Equity Research

Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Compugen (CGEN) delivered earnings and revenue surprises of -33.33% and 38.35%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Fortress Biotech (FBIO) delivered earnings and revenue surprises of -9.09% and 27.56%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Biorestorative Therapies, Inc. (BRTX) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Biorestorative Therapies (BRTX) delivered earnings and revenue surprises of -75% and 91.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Regenxbio (RGNX) delivered earnings and revenue surprises of -70.73% and 19.07%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

McKesson (MCK) Tops Q4 Earnings Estimates

by Zacks Equity Research

McKesson (MCK) delivered earnings and revenue surprises of 3.16% and 3.08%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Compugen (CGEN) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Compugen (CGEN) delivered earnings and revenue surprises of -200% and 91.58%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Compugen (CGEN) Q3 Earnings and Revenues Lag Estimates

by Zacks Equity Research

Compugen (CGEN) delivered earnings and revenue surprises of -83.33% and 3.05%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Compugen Gears Up to Report Q3 Earnings: Here's What to Expect

by Zacks Equity Research

On CGEN's third-quarter 2024 earnings call, investors' focus is likely to be on updates on its pipeline candidates being studied for cancer immunotherapies.

Zacks Equity Research

Compugen (CGEN) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Compugen (CGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Equity Research

Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?

by Zacks Equity Research

Compugen (CGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Zacks Equity Research

Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Compugen (CGEN) delivered earnings and revenue surprises of 75% and 150.54%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Alterity (ATHE) Up on Interim Data From Advance MSA Study

by Zacks Equity Research

Alterity (ATHE) posts positive interim data from the phase II ATH434-202 study evaluating its lead candidate ATH434 for treating patients with multiple system atrophy. Stock rises.

Zacks Equity Research

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data

by Zacks Equity Research

Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.

Zacks Equity Research

Kazia Therapeutics (KZIA) Soars 490% in a Week: Here's Why

by Zacks Equity Research

Kazia (KZIA) surges after positive data from a phase II/III study on its lead pipeline drug in patients with glioblastoma. Based on this data, it plans to seek an accelerated nod from the FDA.